Serum hepcidin predicts uremic accelerated atherosclerosis in chronic hemodialysis patients with diabetic nephropathy

Han Li, Su-Juan Feng, Lu-Lu Su

  • 1Institute of Uro-Nephrology, Beijing Chao-Yang Hospital, Capital Medical University, Beijng 100020, China.

Insights

Elevated serum hepcidin levels are linked to accelerated atherosclerosis in chronic hemodialysis patients with diabetic nephropathy. This suggests iron metabolism and hepcidin abnormalities may drive this condition.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Endocrinology

Background:

  • Hepcidin regulates body iron stores and is implicated in anemia of chronic disease.
  • Atherosclerotic cardiovascular disease is a major cause of mortality in chronic hemodialysis (CHD) patients.
  • Diabetic nephropathy (DN) complicates CHD, increasing cardiovascular risk.

Purpose of the Study:

  • To investigate the relationship between serum hepcidin and uremic accelerated atherosclerosis (UAAS) in CHD patients with DN.
  • To compare hepcidin levels in CHD patients with and without DN.

Main Methods:

  • Serum hepcidin-25 levels were measured using liquid chromatography-tandem mass spectrometry in 78 CHD/DN and 86 CHD/non-DN patients.
  • Interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) levels were quantified via ELISA.
  • Common carotid artery intima media thickness (CCA-IMT) was assessed as a marker of atherosclerosis.

Main Results:

  • Serum hepcidin-25 was significantly higher in CHD/DN patients compared to CHD/non-DN patients.
  • Hepcidin-25 positively correlated with ferritin, hs-CRP, TNF-α, and IL-6 in CHD/DN patients.
  • CCA-IMT, hs-CRP, and hepcidin-25 levels were elevated in CHD/DN patients; CCA-IMT correlated with hepcidin, hs-CRP, and LDL-C.

Conclusions:

  • Findings suggest a link between iron metabolism, hepcidin dysregulation, and the development of UAAS in CHD/DN.
  • Abnormalities in hepcidin may contribute to accelerated atherosclerosis in this patient population.
Abstract

Related Concept Videos

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
315
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
1.9K
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
3.5K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
645
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
353
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
1.2K